(19)
(11) EP 1 874 742 A1

(12)

(43) Date of publication:
09.01.2008 Bulletin 2008/02

(21) Application number: 06724332.9

(22) Date of filing: 13.04.2006
(51) International Patent Classification (IPC): 
C07D 263/56(2006.01)
C07D 413/04(2006.01)
C07D 413/10(2006.01)
(86) International application number:
PCT/EP2006/003445
(87) International publication number:
WO 2006/108671 (19.10.2006 Gazette 2006/42)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 15.04.2005 GB 0507695

(71) Applicants:
  • Novartis AG
    4056 Basel (CH)

    BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR 
  • NOVARTIS-PHARMA GMBH
    1230 Vienna (AT)

    AT 

(72) Inventors:
  • BILLICH, Andreas, Novartis Instit. for Biomedical
    A-1235 Vienna (AT)
  • GSTACH, Hubert, Novartis Institutes for Biomedical
    A-1235 Vienna (AT)
  • LEHR, Philipp, Novartis Institutes for Biomedical
    A-1235 Vienna (AT)

(74) Representative: Schaller, Hans 
Novartis AG Corporate Intellectual Property
4002 Basel
4002 Basel (CH)

   


(54) 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES